Cellectis Shares outstanding
What is the Shares outstanding of Cellectis?
The Shares outstanding of Cellectis is 72.094M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Health Care sector on NASDAQ compared to Cellectis
What does Cellectis do?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Companies with shares outstanding similar to Cellectis
- Shanghai MicroPort Endovascular MedTech Co has Shares outstanding of 71.978M
- BlackRock Municipal Income Fund Inc has Shares outstanding of 71.992M
- Triple has Shares outstanding of 71.996M
- Satin Creditcare Network has Shares outstanding of 72.020M
- Global Net Lease has Shares outstanding of 72.025M
- Stockmann Oyj Abp has Shares outstanding of 72.049M
- Cellectis has Shares outstanding of 72.094M
- Cloud DX has Shares outstanding of 72.094M
- Bioasis Technologies has Shares outstanding of 72.144M
- Urban Exposure Plc has Shares outstanding of 72.156M
- Titan International has Shares outstanding of 72.159M
- BGR Systems has Shares outstanding of 72.162M
- BGR Systems has Shares outstanding of 72.162M